Identification of cancer antigens: Impact on development of cancer immunotherapies

Cancer Journal

Volumn 6, Issue SUPPL. 3, 2000, Pages

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; HUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNIZATION, PASSIVE; NEOPLASMS;

EID: 0033929414     PISSN: 15289117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-913.
2. Rosenberg SA, Yang JC, White DE et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 1998;228:307-319.
3. Van Pel A, Van der Bruggen P, Coulie PG et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-250.
4. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18:175-182.
5. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-287.
6. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86:1159-1166.
7. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462.
8. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519.
9. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother 1996;19:81-84.
10. Robbins PF, El-Gamil M, Li Y et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-5950.
11. Wang R-F, Robbins PF, Kawakami Y et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181:799-804.
12. Wang R-F, Parkhurst MR, Kawakami Y et al. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 1996;183:1131-1140.
13. Robbins PF, El-Gamil M, Li YF et al. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor-infiltrating lymphocytes. J Exp Med 1996;183:1185-1192.
14. Robbins PF, El-Gamil M, Li F et al. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 1997;159:303-308.
15. Wang R-F, Johnston SL, Zen G et al., A breast and melanoma-shared tumor; T-cell responses to antigenic peptides translated from different open reading frames. J Immunol 1998;161:3598-3606.
16. Robbins PF, El-Gamil M, Kawakami Y et al. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-3126.
17. Wang R-F, Johnston SL, Southwood S et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 1998;160:890-897.
18. Skipper JCA, Kittleson DJ, Henderickson RC et al. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996;157:5027-5033.
19. Kittlesen DJ, Thompson LW, Gulden PH et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implication for tumor vaccine development. J Immunol 1998;160:2099-2106.
20. Wolfel T, Van Pel A, Brichard Vet al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-764.
21. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-534.
22. Topalian SL, Rivoltini L, Mancini M et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-9465.
23. Topalian SL, Rivoltini L, Mancini M et al. Melanoma-specific CD4+ T lymphocyte recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 1994;58:69-79.
24. Pieper R, Christian RE, Gonzales MI et al. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells. J Exp Med 1999;189:757-766.
25. Wang R-F, Wang X, Atwood AL et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-1354.
26. Wang R-F, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med 1999;189:1659-1668.
27. Rosenberg SA, Zhai Y, Yang JC et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-1900.
28. Kawakami Y, Eliyahu S, Sakaguchi K et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
29. Kawakami Y, Eliyahu S, Jennings C et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3461-3468.
30. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
31. Cormier JN, Salgaller ML, Prevette T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44.
32. Salgaller ML, Marincola FM, Cormier JN et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996;56:4749-4757.
33. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999;163:1690-1695.
34. Dudley ME, Nishimura MI, Holt AKC et al. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999;22:288-298.
35. Rosenberg SA, Aebersold PM, Cornetta K et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990;323:570-578.
36. Hwu P, Shafer GE, Treisman J et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med 1993;178:361-366.
37. Cole DJ, Weil DP, Shilyansky J et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995;55:748-752.